Yeast as a humanized model organism for biotransformation-related toxicity

Current Drug Metabolism

Volumn 13, Issue 10, 2012, Pages 1464-1475

  Van Leeuwen, Jolanda S ^a,b   Vermeulen, Nico P E ^a   Vos, J Chris ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Biotransformation; Cytochrome P450 metabolism; Model systems; Yeast

Indexed keywords

ADRENODOXIN; AFLATOXIN B1; ALDOSTERONE SYNTHASE; CANAVANINE; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 17; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2B1; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DICLOFENAC; DIMETHYLNITROSAMINE; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; FERREDOXIN NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE REDUCTASE; GLUTATHIONE TRANSFERASE; OXYGENASE INHIBITOR; PARAQUAT; RAD54 PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; STERIGMATOCYSTIN; STEROID 21 MONOOXYGENASE; SULFOTRANSFERASE; UNINDEXED DRUG; XENOBIOTIC AGENT;

AMINO TERMINAL SEQUENCE; ARTICLE; BIOTRANSFORMATION; CELL ASSAY; CELL CULTURE; CELL CYCLE REGULATION; CELL STRAIN V 79; CHO CELL; CONGESTIVE HEART FAILURE; CRYOPRESERVATION; CUNNINGHAMELLA; CYTOTOXICITY; DEMETHYLATION; DNA DAMAGE; DNA REPAIR; DRUG GLUCURONIDATION; DRUG SAFETY; DRUG TRANSPORT; ENZYME DEGRADATION; ESCHERICHIA COLI; EUKARYOTE; EUKARYOTIC CELL; EXPERIMENTAL ANIMAL; GENE EXPRESSION; GENETIC ASSOCIATION; GENOTOXICITY; HETEROLOGOUS EXPRESSION; IC 50; MAMMAL; MUTAGENICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REPORTER GENE; RESPIRATORY FAILURE; SACCHAROMYCES CEREVISIAE; SCHIZOSACCHAROMYCES POMBE; YARROWIA LIPOLYTICA; YEAST; YEAST CELL;

BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; DRUG EVALUATION, PRECLINICAL; DRUG TOXICITY; HUMANS; MODELS, BIOLOGICAL; PHARMACOKINETICS; SACCHAROMYCES CEREVISIAE; TOXICITY TESTS;

EID: 84870443683     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920012803762783     Document Type: Article

References (151)

1. Kola, I.; Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov., 2004, 3, 711-715.
2. Innovative Medicines Initiative. Strategic Research Agenda. 2006.
3. Liebler, D. C.; Guengerich, F. P. Elucidating mechanisms of drug-induced toxicity. Nat. Rev. Drug Discov., 2005, 4, 410-420.
4. Guengerich, F. P.; MacDonald, J. S. Applying mechanisms of chemical toxicity to predict drug safety. Chem. Res. Toxicol., 2007, 20, 344-369.
5. Williams, J. A.; Hyland, R.; Jones, B. C.; Smith, D. A.; Hurst, S.; Goosen, T. C.; Peterkin, V.; Koup, J. R.; Ball, S. E. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab. Dispos., 2004, 32, 1201-1208.
6. FDA. Guidance for industry: safety testing for drug metabolites. 2008.
7. Guengerich, F. P. Cytochrome P450 and chemical toxicology. Chem. Res. Toxicol., 2008, 21, 70-83.
8. Lee, S. S.; Buters, J. T.; Pineau, T.; Fernandez-Salguero, P.; Gonzalez, F. J. Role of CYP2E1 in the hepatotoxicity of acetaminophen. J. Biol. Chem., 1996, 271, 12063-12067.
9. Bedard, L. L.; Massey, T. E. Aflatoxin B1-induced DNA damage and its repair. Cancer Lett., 2006, 241, 174-183.
10. Dekant, W. Chemical-induced nephrotoxicity mediated by glutathione S-conjugate formation. Toxicol. Lett., 2001, 124, 21-36.
11. Sawamura, R.; Okudaira, N.; Watanabe, K.; Murai, T.; Kobayashi, Y.; Tachibana, M.; Ohnuki, T.; Masuda, K.; Honma, H.; Kurihara, A.; Okazaki, O. Predictability of idiosyncratic drug toxicity risk for carboxylic acid-containing drugs based on the chemical stability of acyl glucuronide. Drug Metab. Dispos., 2010, 38, 1857-1864.
12. Glatt, H. Sulfotransferases in the bioactivation of xenobiotics. Chem. Biol. Interact., 2000, 129, 141-170.
13. van Waterschoot, R. A.; Schinkel, A. H. A critical analysis of the interplay between cytochrome P450 3A and P-glycoprotein: recent insights from knockout and transgenic mice. Pharmacol. Rev., 2011, 63, 390-410.
14. Decleves, X.; Jacob, A.; Yousif, S.; Shawahna, R.; Potin, S.; Scherrmann, J. M. Interplay of drug metabolizing CYP450 enzymes and ABC transporters in the blood-brain barrier. Curr. Drug Metab., 2011, 12, 732-741.
15. Johansson, I.; Ingelman-Sundberg, M. Genetic polymorphism and toxicology-with emphasis on cytochrome p450. Toxicol. Sci., 2011, 120, 1-13.
16. Tang, C.; Prueksaritanont, T. Use of in vivo animal models to assess pharmacokinetic drug-drug interactions. Pharm. Res., 2010, 27, 1772-1787.
17. Vermeir, M.; Annaert, P.; Mamidi, R. N.; Roymans, D.; Meuldermans, W.; Mannens, G. Cell-based models to study hepatic drug metabolism and enzyme induction in humans. Expert Opin. Drug Metab. Toxicol., 2005, 1, 75-90.
18. Friedberg, T.; Pritchard, M. P.; Bandera, M.; Hanlon, S. P.; Yao, D.; McLaughlin, L. A.; Ding, S.; Burchell, B.; Wolf, C. R. Merits and limitations of recombinant models for the study of human P450-mediated drug metabolism and toxicity: an intralaboratory comparison. Drug Metab. Rev., 1999, 31, 523-544.
19. Ho, C. H.; Piotrowski, J.; Dixon, S. J.; Baryshnikova, A.; Costanzo, M.; Boone, C. Combining functional genomics and chemical biology to identify targets of bioactive compounds. Curr. Opin. Chem. Biol., 2011, 15, 66-78.
20. Smith, A. M.; Ammar, R.; Nislow, C.; Giaever, G. A survey of yeast genomic assays for drug and target discovery. Pharmacol. Ther., 2010, 127, 156-164.
21. Sturgeon, C. M.; Kemmer, D.; Anderson, H. J.; Roberge, M. Yeast as a tool to uncover the cellular targets of drugs. Biotechnol. J., 2006, 1, 289-298.
22. Routledge, E. J.; Sumpter, J. P. Estrogenic activity of surfactants and some of their degradation products assessed using a recombinant yeast screen. Environ. Toxicol. Chem., 1996, 15, 241-248.
23. Westerink, W. M.; Stevenson, J. C.; Lauwers, A.; Griffioen, G.; Horbach, G. J.; Schoonen, W. G. Evaluation of the Vitotox and RadarScreen assays for the rapid assessment of genotoxicity in the early research phase of drug development. Mutat. Res., 2009, 676, 113-130.
24. Guo, Y.; Breeden, L. L.; Zarbl, H.; Preston, B. D.; Eaton, D. L. Expression of a human cytochrome P450 in yeast permits analysis of pathways for response to and repair of aflatoxin-induced DNA damage. Mol. Cell Biol., 2005, 25, 5823-5833.
25. Guo, Y.; Breeden, L. L.; Fan, W.; Zhao, L. P.; Eaton, D. L.; Zarbl, H. Analysis of cellular responses to aflatoxin B(1) in yeast expressing human cytochrome P450 1A2 using cDNA microarrays. Mutat. Res., 2006, 593, 121-142.
26. Kaplanski, C.; Wild, C. P.; Sengstag, C. Rearrangements in minisatellite sequences induced by aflatoxin B1 in a metabolically competent strain of Saccharomyces cerevisiae. Carcinogenesis, 1998, 19, 1673-1678.
27. Kelly, E. J.; Erickson, K. E.; Sengstag, C.; Eaton, D. L. Expression of human microsomal epoxide hydrolase in Saccharomyces cerevisiae reveals a functional role in aflatoxin B1 detoxification. Toxicol. Sci., 2002, 65, 35-42.
28. Li, X.; Millson, S. H.; Coker, R. D.; Evans, I. H. Cloning and expression of Penicillium minioluteum dextranase in Saccharomyces cerevisiae and its exploitation as a reporter in the detection of mycotoxins. Biotechnol. Lett., 2006, 28, 1955-1964.
29. Li, X.; Millson, S.; Coker, R.; Evans, I. A sensitive bioassay for the mycotoxin aflatoxin B(1), which also responds to the mycotoxins aflatoxin G(1) and T-2 toxin, using engineered baker's yeast. J. Microbiol. Methods, 2009, 77, 285-291.
30. Sengstag, C.; Weibel, B.; Fasullo, M. Genotoxicity of aflatoxin B1: evidence for a recombination-mediated mechanism in Saccharomyces cerevisiae. Cancer Res., 1996, 56, 5457-5465.
31. Black, S. M.; Ellard, S.; Meehan, R. R.; Parry, J. M.; Adesnik, M.; Beggs, J. D.; Wolf, C. R. The expression of cytochrome P450IIB1 in Saccharomyces cerevisiae results in an increased mutation frequency when exposed to cyclophosphamide. Carcinogenesis, 1989, 10, 2139-2143.
32. Black, S. M.; Ellard, S.; Parry, J. M.; Wolf, C. R. Increased sterigmatocystin-induced mutation frequency in Saccharomyces cerevisiae expressing cytochrome P450 CYP2B1. Biochem. Pharmacol., 1992, 43, 374-376.
33. Del Carratore, M. R.; Mezzatesta, C.; Hidestrand, M.; Neve, P.; Amato, G.; Gervasi, P. G. Cloning and expression of rat CYP2E1 in Saccharomyces cerevisiae: detection of genotoxicity of Nalkylformamides. Environ. Mol. Mutagen., 2000, 36, 97-104.
34. Sengstag, C.; Würgler, F. E. DNA recombination induced by aflatoxin B1 activated by cytochrome P450 1A enzymes. Mol. Carcinog., 1994, 11, 227-235.
35. Walsh, L.; Hastwell, P. W.; Keenan, P. O.; Knight, A. W.; Billinton, N.; Walmsley, R. M. Genetic modification and variations in solvent increase the sensitivity of the yeast RAD54-GFP genotoxicity assay. Mutagenesis, 2005, 20, 317-327.
36. Gomez-Lechon, M. J.; Castell, J. V.; Donato, M. T. Hepatocytes-the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo. Chem. Biol. Interact., 2007, 168, 30-50.
37. Li, A. P. Metabolism Comparative Cytotoxicity Assay (MCCA) and Cytotoxic Metabolic Pathway Identification Assay (CMPIA) with cryopreserved human hepatocytes for the evaluation of metabolism-based cytotoxicity in vitro: proof-of-concept study with aflatoxin B1. Chem. Biol. Interact., 2009, 179, 4-8.
38. Raungrut, P.; Uchaipichat, V.; Elliot, D. J.; Janchawee, B.; Somogyi, A. A.; Miners, J. O. In vitro-in vivo extrapolation predicts drug-drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans. J. Pharmacol. Exp. Ther., 2010, 334, 609-618.
39. Wang, E. J.; Lew, K.; Casciano, C. N.; Clement, R. P.; Johnson, W. W. Interaction of common azole antifungals with P glycoprotein. Antimicrob. Agents Chemother., 2002, 46, 160-165.
40. LeCluyse, E. L. Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur. J. Pharm. Sci., 2001, 13, 343-368.
41. Li, A. P. Human hepatocytes: isolation, cryopreservation and applications in drug development. Chem. Biol. Interact., 2007, 168, 16-29.
42. Sohlenius-Sternbeck, A. K.; Schmidt, S. Impaired glutathione-conjugating capacity by cryopreserved human and rat hepatocytes. Xenobiotica, 2005, 35, 727-736.
43. Elferink, M. G.; Olinga, P.; van Leeuwen, E. M.; Bauerschmidt, S.; Polman, J.; Schoonen, W. G.; Heisterkamp, S. H.; Groothuis, G. M. Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol. Appl. Pharmacol., 2011, 253, 57-69.
44. Renwick, A. B.; Watts, P. S.; Edwards, R. J.; Barton, P. T.; Guyonnet, I.; Price, R. J.; Tredger, J. M.; Pelkonen, O.; Boobis, A. R.; Lake, B. G. Differential maintenance of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab. Dispos., 2000, 28, 1202-1209.
45. Ek, M.; Soderdahl, T.; Kuppers-Munther, B.; Edsbagge, J.; Andersson, T. B.; Bjorquist, P.; Cotgreave, I.; Jernstrom, B.; Ingelman-Sundberg, M.; Johansson, I. Expression of drug metabolizing enzymes in hepatocyte-like cells derived from human embryonic stem cells. Biochem. Pharmacol., 2007, 74, 496-503.
46. Guillouzo, A.; Corlu, A.; Aninat, C.; Glaise, D.; Morel, F.; Guguen-Guillouzo, C. The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem. Biol. Interact., 2007, 168, 66-73.
47. Darnell, M.; Schreiter, T.; Zeilinger, K.; Urbaniak, T.; Soderdahl, T.; Rossberg, I.; Dillner, B.; Berg, A. L.; Gerlach, J. C.; Andersson, T. B. Cytochrome P450-dependent metabolism in HepaRG cells cultured in a dynamic three-dimensional bioreactor. Drug Metab. Dispos., 2011, 39, 1131-1138.
48. Schutte, M.; Fox, B.; Baradez, M. O.; Devonshire, A.; Minguez, J.; Bokhari, M.; Przyborski, S.; Marshall, D. Rat primary hepatocytes show enhanced performance and sensitivity to acetaminophen during three-dimensional culture on a polystyrene scaffold designed for routine use. Assay Drug Dev. Technol., 2011, 9, 475-486.
49. Amadio, J.; Murphy, C. D. Biotransformation of fluorobiphenyl by Cunninghamella elegans. Appl. Microbiol. Biotechnol., 2010, 86, 345-351.
50. Asha, S.; Vidyavathi, M. Cunninghamella-a microbial model for drug metabolism studies-a review. Biotechnol. Adv., 2009, 27, 16-29.
51. Lee, M. Y.; Kumar, R. A.; Sukumaran, S. M.; Hogg, M. G.; Clark, D. S.; Dordick, J. S. Three-dimensional cellular microarray for high-throughput toxicology assays. Proc. Natl. Acad. Sci. USA, 2008, 105, 59-63.
52. Ma, B.; Zhang, G.; Qin, J.; Lin, B. Characterization of drug metabolites and cytotoxicity assay simultaneously using an integrated microfluidic device. Lab. Chip., 2009, 9, 232-238.
53. Gautier, J. C.; Urban, P.; Beaune, P.; Pompon, D. Engineered yeast cells as model to study coupling between human xenobiotic metabolizing enzymes. Simulation of the two first steps of benzo [a]pyrene activation. Eur. J. Biochem., 1993, 211, 63-72.
54. Kranendonk, M.; Laires, A.; Rueff, J.; Estabrook, W. R.; Vermeulen, N. P. Heterologous expression of xenobiotic mammalian-metabolizing enzymes in mutagenicity tester bacteria: an update and practical considerations. Crit. Rev. Toxicol., 2000, 30, 287-306.
55. Fralick, J. A.; Burns-Keliher, L. L. Additive effect of tolC and rfa mutations on the hydrophobic barrier of the outer membrane of Escherichia coli K-12. J. Bacteriol., 1994, 176, 6404-6406.
56. Sawada, M.; Kamataki, T. Genetically engineered cells stably expressing cytochrome P450 and their application to mutagen assays. Mutat. Res., 1998, 411, 19-43.
57. Glatt, H.; Schneider, H.; Liu, Y. V79-hCYP2E1-hSULT1A1, a cell line for the sensitive detection of genotoxic effects induced by carbohydrate pyrolysis products and other food-borne chemicals. Mutat. Res., 2005, 580, 41-52.
58. Chaung, W.; Mi, L. J.; Boorstein, R. J. The p53 status of Chinese hamster V79 cells frequently used for studies on DNA damage and DNA repair. Nucleic Acids Res., 1997, 25, 992-994.
59. Hu, T.; Miller, C. M.; Ridder, G. M.; Aardema, M. J. Characterization of p53 in Chinese hamster cell lines CHO-K1, CHO-WBL, and CHL: implications for genotoxicity testing. Mutat. Res., 1999, 426, 51-62.
60. Knight, A. W.; Billinton, N.; Cahill, P. A.; Scott, A.; Harvey, J. S.; Roberts, K. J.; Tweats, D. J.; Keenan, P. O.; Walmsley, R. M. An analysis of results from 305 compounds tested with the yeast RAD54-GFP genotoxicity assay (GreenScreen GC)-including relative predictivity of regulatory tests and rodent carcinogenesis and performance with autofluorescent and coloured compounds. Mutagenesis, 2007, 22, 409-416.
61. Hughes, T. R. Yeast and drug discovery. Funct. Integr. Genomics, 2002, 2, 199-211.
62. McGary, K. L.; Park, T. J.; Woods, J. O.; Cha, H. J.; Wallingford, J. B.; Marcotte, E. M. Systematic discovery of nonobvious human disease models through orthologous phenotypes. Proc. Natl. Acad. Sci. USA, 2010, 107, 6544-6549.
63. Bharucha, N.; Kumar, A. Yeast genomics and drug target identification. Comb. Chem. High Throughput Screen., 2007, 10, 618-634.
64. Mager, W. H.; Winderickx, J. Yeast as a model for medical and medicinal research. Trends Pharmacol. Sci., 2005, 26, 265-273.
65. Menacho-Marquez, M.; Murguia, J. R. Yeast on drugs: Saccharomyces cerevisiae as a tool for anticancer drug research. Clin. Transl. Oncol., 2007, 9, 221-228.
66. Giaever, G.; Chu, A. M.; Ni, L.; Connelly, C.; Riles, L.; Veronneau, S.; Dow, S.; Lucau-Danila, A.; Anderson, K.; Andre, B.; Arkin, A. P.; Astromoff, A.; El-Bakkoury, M.; Bangham, R.; Benito, R.; Brachat, S.; Campanaro, S.; Curtiss, M.; Davis, K.; Deutschbauer, A.; Entian, K. D.; Flaherty, P.; Foury, F.; Garfinkel, D. J.; Gerstein, M.; Gotte, D.; Guldener, U.; Hegemann, J. H.; Hempel, S.; Herman, Z.; Jaramillo, D. F.; Kelly, D. E.; Kelly, S. L.; Kotter, P.; LaBonte, D.; Lamb, D. C.; Lan, N.; Liang, H.; Liao, H.; Liu, L.; Luo, C.; Lussier, M.; Mao, R.; Menard, P.; Ooi, S. L.; Revuelta, J. L.; Roberts, C. J.; Rose, M.; Ross-Macdonald, P.; Scherens, B.; Schimmack, G.; Shafer, B.; Shoemaker, D. D.; Sookhai-Mahadeo, S.; Storms, R. K.; Strathern, J. N.; Valle, G.; Voet, M.; Volckaert, G.; Wang, C. Y.; Ward, T. R.; Wilhelmy, J.; Winzeler, E. A.; Yang, Y.; Yen, G.; Youngman, E.; Yu, K.; Bussey, H.; Boeke, J. D.; Snyder, M.; Philippsen, P.; Davis, R. W.; Johnston, M. Functional profiling of the Saccharomyces cerevisiae genome. Nature, 2002, 418, 387-391.
67. Magtanong, L.; Ho, C. H.; Barker, S. L.; Jiao, W.; Baryshnikova, A.; Bahr, S.; Smith, A. M.; Heisler, L. E.; Choy, J. S.; Kuzmin, E.; Andrusiak, K.; Kobylianski, A.; Li, Z.; Costanzo, M.; Basrai, M. A.; Giaever, G.; Nislow, C.; Andrews, B.; Boone, C. Dosage suppression genetic interaction networks enhance functional wiring diagrams of the cell. Nat. Biotechnol., 2011, 29, 505-511.
68. Yu, L.; Lopez, A.; Anaflous, A.; El Bali, B.; Hamal, A.; Ericson, E.; Heisler, L. E.; McQuibban, A.; Giaever, G.; Nislow, C.; Boone, C.; Brown, G. W.; Bellaoui, M. Chemical-genetic profiling of imidazo [1,2-a]pyridines and -pyrimidines reveals target pathways conserved between yeast and human cells. PLoS Genet., 2008, 4, e1000284.
69. Baetz, K.; McHardy, L.; Gable, K.; Tarling, T.; Reberioux, D.; Bryan, J.; Andersen, R. J.; Dunn, T.; Hieter, P.; Roberge, M. Yeast genome-wide drug-induced haploinsufficiency screen to determine drug mode of action. Proc. Natl. Acad. Sci. USA, 2004, 101, 4525-4530.
70. Lum, P. Y.; Armour, C. D.; Stepaniants, S. B.; Cavet, G.; Wolf, M. K.; Butler, J. S.; Hinshaw, J. C.; Garnier, P.; Prestwich, G. D.; Leonardson, A.; Garrett-Engele, P.; Rush, C. M.; Bard, M.; Schimmack, G.; Phillips, J. W.; Roberts, C. J.; Shoemaker, D. D. Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. Cell, 2004, 116, 121-137.
71. Cocheme, H. M.; Murphy, M. P. Complex I is the major site of mitochondrial superoxide production by paraquat. J. Biol. Chem., 2008, 283, 1786-1798.
72. Steinmetz, L. M.; Scharfe, C.; Deutschbauer, A. M.; Mokranjac, D.; Herman, Z. S.; Jones, T.; Chu, A. M.; Giaever, G.; Prokisch, H.; Oefner, P. J.; Davis, R. W. Systematic screen for human disease genes in yeast. Nat. Genet., 2002, 31, 400-404.
73. van Leeuwen, J. S.; Orij, R.; Luttik, M. A.; Smits, G. J.; Vermeulen, N. P.; Vos, J. C. Subunits Rip1p and Cox9p of the respiratory chain contribute to diclofenac-induced mitochondrial dysfunction. Microbiology, 2011, 157, 685-694.
74. Balsiger, H. A.; de la Torre, R.; Lee, W. Y.; Cox, M. B. A fourhour yeast bioassay for the direct measure of estrogenic activity in wastewater without sample extraction, concentration, or sterilization. Sci. Total. Environ., 2010, 408, 1422-1429.
75. Sanseverino, J.; Gupta, R. K.; Layton, A. C.; Patterson, S. S.; Ripp, S. A.; Saidak, L.; Simpson, M. L.; Schultz, T. W.; Sayler, G. S. Use of Saccharomyces cerevisiae BLYES expressing bacterial bioluminescence for rapid, sensitive detection of estrogenic compounds. Appl. Environ. Microbiol., 2005, 71, 4455-4460.
76. Cahill, P. A.; Knight, A. W.; Billinton, N.; Barker, M. G.; Walsh, L.; Keenan, P. O.; Williams, C. V.; Tweats, D. J.; Walmsley, R. M. The GreenScreen genotoxicity assay: a screening validation programme. Mutagenesis, 2004, 19, 105-119.
77. Lichtenberg-Frate, H.; Schmitt, M.; Gellert, G.; Ludwig, J. A yeast-based method for the detection of cyto and genotoxicity. Toxicol. In vitro, 2003, 17, 709-716.
78. Benton, M. G.; Glasser, N. R.; Palecek, S. P. The utilization of a Saccharomyces cerevisiae HUG1P-GFP promoter-reporter construct for the selective detection of DNA damage. Mutat. Res., 2007, 633, 21-34.
79. Jia, X.; Zhu, Y.; Xiao, W. A stable and sensitive genotoxic testing system based on DNA damage induced gene expression in Saccharomyces cerevisiae. Mutat. Res., 2002, 519, 83-92.
80. van Gompel, J.; Woestenborghs, F.; Beerens, D.; Mackie, C.; Cahill, P. A.; Knight, A. W.; Billinton, N.; Tweats, D. J.; Walmsley, R. M. An assessment of the utility of the yeast GreenScreen assay in pharmaceutical screening. Mutagenesis, 2005, 20, 449-454.
81. Schmitt, M.; Schwanewilm, P.; Ludwig, J.; Lichtenberg-Frate, H. Use of PMA1 as a housekeeping biomarker for assessment of toxicant-induced stress in Saccharomyces cerevisiae. Appl. Environ. Microbiol., 2006, 72, 1515-1522.
82. Abolmaali, S.; Mitterbauer, R.; Spadiut, O.; Peruci, M.; Weindorfer, H.; Lucyshyn, D.; Ellersdorfer, G.; Lemmens, M.; Moll, W. D.; Adam, G. Engineered bakers yeast as a sensitive bioassay indicator organism for the trichothecene toxin deoxynivalenol. J. Microbiol. Methods, 2008, 72, 306-312.
83. Keenan, P. O.; Knight, A. W.; Billinton, N.; Cahill, P. A.; Dalrymple, I. M.; Hawkyard, C. J.; Stratton-Campbell, D.; Walmsley, R. M. Clear and present danger? The use of a yeast biosensor to monitor changes in the toxicity of industrial effluents subjected to oxidative colour removal treatments. J. Environ. Monit., 2007, 9, 1394-1401.
84. Cresnar, B.; Petric, S. Cytochrome P450 enzymes in the fungal kingdom. Biochim. Biophys. Acta, 2011, 1814, 29-35.
85. van den Brink, H. M.; van Gorcom, R. F.; van den Hondel, C. A.; Punt, P. J. Cytochrome P450 enzyme systems in fungi. Fungal Genet. Biol., 1998, 23, 1-17.
86. Aoyama, Y.; Yoshida, Y.; Sonoda, Y.; Sato, Y. Deformylation of 32-oxo-24,25-dihydrolanosterol by the purified cytochrome P-45014DM (lanosterol 14 alpha-demethylase) from yeast evidence confirming the intermediate step of lanosterol 14 alphademethylation. J. Biol. Chem., 1989, 264, 18502-18505.
87. Briza, P.; Eckerstorfer, M.; Breitenbach, M. The sporulation-specific enzymes encoded by the DIT1 and DIT2 genes catalyze a two-step reaction leading to a soluble LL-dityrosine-containing precursor of the yeast spore wall. Proc. Natl. Acad. Sci. USA, 1994, 91, 4524-4528.
88. Kelly, S. L.; Lamb, D. C.; Baldwin, B. C.; Corran, A. J.; Kelly, D. E. Characterization of Saccharomyces cerevisiae CYP61, sterol delta22-desaturase, and inhibition by azole antifungal agents. J. Biol. Chem., 1997, 272, 9986-9988.
89. Kelly, S. L.; Lamb, D. C.; Kelly, D. E. Sterol 22-desaturase, cytochrome P45061, possesses activity in xenobiotic metabolism. FEBS Lett., 1997, 412, 233-235.
90. Choi, J. H.; Lou, W.; Vancura, A. A novel membrane-bound glutathione S-transferase functions in the stationary phase of the yeast Saccharomyces cerevisiae. J. Biol. Chem., 1998, 273, 29915-29922.
91. Collinson, E. J.; Grant, C. M. Role of yeast glutaredoxins as glutathione S-transferases. J. Biol. Chem., 2003, 278, 22492-22497.
92. Castro, F. A.; Herdeiro, R. S.; Panek, A. D.; Eleutherio, E. C.; Pereira, M. D. Menadione stress in Saccharomyces cerevisiae strains deficient in the glutathione transferases. Biochim. Biophys. Acta, 2007, 1770, 213-220.
93. Luikenhuis, S.; Perrone, G.; Dawes, I. W.; Grant, C. M. The yeast Saccharomyces cerevisiae contains two glutaredoxin genes that are required for protection against reactive oxygen species. Mol. Biol. Cell, 1998, 9, 1081-1091.
94. Garcera, A.; Barreto, L.; Piedrafita, L.; Tamarit, J.; Herrero, E. Saccharomyces cerevisiae cells have three Omega class glutathione S-transferases acting as 1-Cys thiol transferases. Biochem. J., 2006, 398, 187-196.
95. McGoldrick, S.; O'Sullivan, S. M.; Sheehan, D. Glutathione transferase-like proteins encoded in genomes of yeasts and fungi: insights into evolution of a multifunctional protein superfamily. FEMS Microbiol. Lett., 2005, 242, 1-12.
96. Zhang, Z. R.; Bai, M.; Wang, X. Y.; Zhou, J. M.; Perrett, S. "Restoration" of glutathione transferase activity by single-site mutation of the yeast prion protein Ure2. J. Mol. Biol., 2008, 384, 641-651.
97. Oeda, K.; Sakaki, T.; Ohkawa, H. Expression of rat liver cytochrome P-450MC cDNA in Saccharomyces cerevisiae. DNA, 1985, 4, 203-210.
98. Fickers, P.; Benetti, P. H.; Wache, Y.; Marty, A.; Mauersberger, S.; Smit, M. S.; Nicaud, J. M. Hydrophobic substrate utilisation by the yeast Yarrowia lipolytica, and its potential applications. FEMS Yeast. Res., 2005, 5, 527-543.
99. Peters, F. T.; Bureik, M.; Maurer, H. H. Biotechnological synthesis of drug metabolites using human cytochrome P450 isozymes heterologously expressed in fission yeast. Bioanalysis, 2009, 1, 821-830.
100. Dumas, B.; Brocard-Masson, C.; Assemat-Lebrun, K.; Achstetter, T. Hydrocortisone made in yeast: metabolic engineering turns a unicellular microorganism into a drug-synthesizing factory. Biotechnol. J., 2006, 1, 299-307.
101. Huang, B.; Guo, J.; Yi, B.; Yu, X.; Sun, L.; Chen, W. Heterologous production of secondary metabolites as pharmaceuticals in Saccharomyces cerevisiae. Biotechnol. Lett., 2008, 30, 1121-1137.
102. Lee, S. Y.; Kim, H. U.; Park, J. H.; Park, J. M.; Kim, T. Y. Metabolic engineering of microorganisms: general strategies and drug production. Drug Discov. Today, 2009, 14, 78-88.
103. Zöllner, A.; Buchheit, D.; Meyer, M. R.; Maurer, H. H.; Peters, F. T.; Bureik, M. Production of human phase 1 and 2 metabolites by whole-cell biotransformation with recombinant microbes. Bioanalysis, 2010, 2, 1277-1290.
104. Winkel, B. S. Metabolic channeling in plants. Annu. Rev. Plant Biol., 2004, 55, 85-107.
105. Zehentgruber, D.; Dragan, C. A.; Bureik, M.; Lutz, S. Challenges of steroid biotransformation with human cytochrome P450 monooxygenase CYP21 using resting cells of recombinant Schizosaccharomyces pombe. J. Biotechnol., 2010, 146, 179-185.
106. Dragan, C. A.; Peters, F. T.; Bour, P.; Schwaninger, A. E.; Schaan, S. M.; Neunzig, I.; Widjaja, M.; Zapp, J.; Kraemer, T.; Maurer, H. H.; Bureik, M. Convenient gram-scale metabolite synthesis by engineered fission yeast strains expressing functional human P450 systems. Appl. Biochem. Biotechnol., 2011, 163, 965-980.
107. Othman, S.; Mansuy-Mouries, V.; Bensoussan, C.; Battioni, P.; Mansuy, D. Hydroxylation of diclofenac: an illustration of the complementary roles of biomimetic metalloporphyrin catalysts and yeasts expressing human cytochromes P450 in drug metabolism studies. Bioorg. Med. Chem., 2000, 3, 751-755.
108. DeJong, J. M.; Liu, Y.; Bollon, A. P.; Long, R. M.; Jennewein, S.; Williams, D.; Croteau, R. B. Genetic engineering of taxol biosynthetic genes in Saccharomyces cerevisiae. Biotechnol. Bioeng., 2006, 93, 212-224.
109. Hawkins, K. M.; Smolke, C. D. Production of benzylisoquinoline alkaloids in Saccharomyces cerevisiae. Nat. Chem. Biol., 2008, 4, 564-573.
110. Ro, D. K.; Paradise, E. M.; Ouellet, M.; Fisher, K. J.; Newman, K. L.; Ndungu, J. M.; Ho, K. A.; Eachus, R. A.; Ham, T. S.; Kirby, J.; Chang, M. C.; Withers, S. T.; Shiba, Y.; Sarpong, R.; Keasling, J. D. Production of the antimalarial drug precursor artemisinic acid in engineered yeast. Nature, 2006, 440, 940-943.
111. Takahashi, S.; Yeo, Y.; Greenhagen, B. T.; McMullin, T.; Song, L.; Maurina-Brunker, J.; Rosson, R.; Noel, J. P.; Chappell, J. Metabolic engineering of sesquiterpene metabolism in yeast. Biotechnol. Bioeng., 2007, 97, 170-181.
112. Ehmer, P. B.; Bureik, M.; Bernhardt, R.; Muller, U.; Hartmann, R. W. Development of a test system for inhibitors of human aldosterone synthase (CYP11B2): screening in fission yeast and evaluation of selectivity in V79 cells. J. Steroid Biochem. Mol. Biol., 2002, 81, 173-179.
113. Dragan, C. A.; Hartmann, R. W.; Bureik, M. A fission yeast-based test system for the determination of IC50 values of anti-prostate tumor drugs acting on CYP21. J. Enzyme Inhib. Med. Chem., 2006, 21, 547-556.
114. Correia, M. A.; Liao, M. Cellular proteolytic systems in P450 degradation: evolutionary conservation from Saccharomyces cerevisiae to mammalian liver. Expert Opin. Drug Metab. Toxicol., 2007, 3, 33-49.
115. Sepuri, N. B.; Yadav, S.; Anandatheerthavarada, H. K.; Avadhani, N. G. Mitochondrial targeting of intact CYP2B1 and CYP2E1 and N-terminal truncated CYP1A1 proteins in Saccharomyces cerevisiae - role of protein kinase A in the mitochondrial targeting of CYP2E1. FEBS J., 2007, 274, 4615-4630.
116. Hanioka, N.; Yamamoto, M.; Tanaka-Kagawa, T.; Jinno, H.; Narimatsu, S. Functional characterization of human cytochrome P4502E1 allelic variants: in vitro metabolism of benzene and toluene by recombinant enzymes expressed in yeast cells. Arch. Toxicol., 2010, 84, 363-371.
117. Omura, T. Structural diversity of cytochrome P450 enzyme system. J. Biochem., 2010, 147, 297-306.
118. Cheng, J.; Wan, D. F.; Gu, J. R.; Gong, Y.; Yang, S. L.; Hao, D. C.; Yang, L. Establishment of a yeast system that stably expresses human cytochrome P450 reductase: application for the study of drug metabolism of cytochrome P450s in vitro. Protein Expr. Purif., 2006, 47, 467-476.
119. Pompon, D.; Perret, A.; Bellamine, A.; Laine, R.; Gautier, J. C.; Urban, P. Genetically engineered yeast cells and their applications. Toxicol. Lett., 1995, 82-83, 815-822.
120. Hayashi, K.; Sakaki, T.; Kominami, S.; Inouye, K.; Yabusaki, Y. Coexpression of genetically engineered fused enzyme between yeast NADPH-P450 reductase and human cytochrome P450 3A4 and human cytochrome b5 in yeast. Arch. Biochem. Biophys., 2000, 381, 164-170.
121. Dumas, B.; Cauet, G.; Lacour, T.; Degryse, E.; Laruelle, L.; Ledoux, C.; Spagnoli, R.; Achstetter, T. 11 beta-hydroxylase activity in recombinant yeast mitochondria. In vivo conversion of 11-deoxycortisol to hydrocortisone. Eur. J. Biochem., 1996, 238, 495-504.
122. Lacour, T.; Achstetter, T.; Dumas, B. Characterization of recombinant adrenodoxin reductase homologue (Arh1p) from yeast. Implication in in vitro cytochrome p45011beta monooxygenase system. J. Biol. Chem., 1998, 273, 23984- 23992.
123. Szczebara, F. M.; Chandelier, C.; Villeret, C.; Masurel, A.; Bourot, S.; Duport, C.; Blanchard, S.; Groisillier, A.; Testet, E.; Costaglioli, P.; Cauet, G.; Degryse, E.; Balbuena, D.; Winter, J.; Achstetter, T.; Spagnoli, R.; Pompon, D.; Dumas, B. Total biosynthesis of hydrocortisone from a simple carbon source in yeast. Nat. Biotechnol., 2003, 21, 143-149.
124. Bureik, M.; Schiffler, B.; Hiraoka, Y.; Vogel, F.; Bernhardt, R. Functional expression of human mitochondrial CYP11B2 in fission yeast and identification of a new internal electron transfer protein, etp1. Biochemistry, 2002, 41, 2311-2321.
125. Schiffler, B.; Bureik, M.; Reinle, W.; Muller, E. C.; Hannemann, F.; Bernhardt, R. The adrenodoxin-like ferredoxin of Schizosaccharomyces pombe mitochondria. J. Inorg. Biochem., 2004, 98, 1229-1237.
126. Hakki, T.; Zearo, S.; Dragan, C. A.; Bureik, M.; Bernhardt, R. Coexpression of redox partners increases the hydrocortisone (cortisol) production efficiency in CYP11B1 expressing fission yeast Schizosaccharomyces pombe. J. Biotechnol., 2008, 133, 351-359.
127. Dragan, C. A.; Blank, L. M.; Bureik, M. Increased TCA cycle activity and reduced oxygen consumption during cytochrome P450-dependent biotransformation in fission yeast. Yeast, 2006, 23, 779-794.
128. Bansal, S.; Liu, C. P.; Sepuri, N. B.; Anandatheerthavarada, H. K.; Selvaraj, V.; Hoek, J.; Milne, G. L.; Guengerich, F. P.; Avadhani, N. G. Mitochondria-targeted cytochrome P450 2E1 induces oxidative damage and augments alcohol-mediated oxidative stress. J. Biol. Chem., 2010, 285, 24609-24619.
129. Engler, K. H.; Coker, R. D.; Evans, I. H. A colorimetric technique for detecting trichothecenes and assessing relative potencies. Appl. Environ. Microbiol., 1999, 65, 1854-1857.
130. Keller-Seitz, M. U.; Certa, U.; Sengstag, C.; Wurgler, F. E.; Sun, M.; Fasullo, M. Transcriptional response of yeast to aflatoxin B1: recombinational repair involving RAD51 and RAD1. Mol. Biol. Cell, 2004, 15, 4321-4336.
131. Parker, J. E.; Merkamm, M.; Manning, N. J.; Pompon, D.; Kelly, S. L.; Kelly, D. E. Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homologous locus. Antimicrob. Agents Chemother., 2008, 52, 3597-3603.
132. van Leeuwen, J. S.; Vredenburg, G.; Dragovic, S.; Tjong, T. F.; Vos, J. C.; Vermeulen, N. P. Metabolism related toxicity of diclofenac in yeast as model system. Toxicol. Lett., 2011, 200, 162-168.
133. Munro, A. W.; Leys, D. G.; McLean, K. J.; Marshall, K. R.; Ost, T. W.; Daff, S.; Miles, C. S.; Chapman, S. K.; Lysek, D. A.; Moser, C. C.; Page, C. C.; Dutton, P. L. P450 BM3: the very model of a modern flavocytochrome. Trends Biochem. Sci., 2002, 27, 250-257.
134. Damsten, M. C.; van Vugt-Lussenburg, B. M.; Zeldenthuis, T.; de Vlieger, J. S.; Commandeur, J. N.; Vermeulen, N. P. Application of drug metabolising mutants of cytochrome P450 BM3 (CYP102A1) as biocatalysts for the generation of reactive metabolites. Chem. Biol. Interact., 2008, 171, 96-107.
135. van Leeuwen, J. S.; Unlu, B.; Vermeulen, N. P.; Vos, J. C. Differential involvement of mitochondrial dysfunction, cytochrome P450 activity, and active transport in the toxicity of structurally related NSAIDs. Toxicol. In vitro, 2012, 26, 197-205.
136. Dragan, C. A.; Buchheit, D.; Bischoff, D.; Ebner, T.; Bureik, M. Glucuronide production by whole-cell biotransformation using genetically engineered fission yeast Schizosaccharomyces pombe. Drug Metab. Dispos., 2010, 38, 509-515.
137. Iwano, H.; Yokota, H.; Ohgiya, S.; Yotumoto, N.; Yuasa, A. A critical amino acid residue, asp446, in UDPglucuronosyltransferase. Biochem. J., 1997, 325 (Pt 3), 587-591.
138. Toghrol, F.; Kimura, T.; Owens, I. S. Expression of UDP- glucuronosyltransferase cDNA in Saccharomyces cerevisiae as a membrane-bound and as a cytosolic form. Biochemistry, 1990, 29, 2349-2356.
139. Lattard, V.; Fondeur-Gelinotte, M.; Gulberti, S.; Jacquinet, J. C.; Boudrant, J.; Netter, P.; Magdalou, J.; Ouzzine, M.; Fournel-Gigleux, S. Purification and characterization of a soluble form of the recombinant human galactose-beta1,3-glucuronosyltransferase I expressed in the yeast Pichia pastoris. Protein Expr. Purif., 2006, 47, 137-143.
140. Ouzzine, M.; Antonio, L.; Burchell, B.; Netter, P.; Fournel-Gigleux, S.; Magdalou, J. Importance of histidine residues for the function of the human liver UDP-glucuronosyltransferase UGT1A6: evidence for the catalytic role of histidine 370. Mol. Pharmacol., 2000, 58, 1609-1615.
141. Ouzzine, M.; Gulberti, S.; Netter, P.; Magdalou, J.; Fournel-Gigleux, S. Structure/function of the human Ga1beta1,3-glucuronosyltransferase. Dimerization and functional activity are mediated by two crucial cysteine residues. J. Biol. Chem., 2000, 275, 28254-28260.
142. Ouzzine, M.; Magdalou, J.; Burchell, B.; Fournel-Gigleux, S. An internal signal sequence mediates the targeting and retention of the human UDP-glucuronosyltransferase 1A6 to the endoplasmic reticulum. J. Biol. Chem., 1999, 274, 31401-31409.
143. Ikushiro, S.; Sahara, M.; Emi, Y.; Yabusaki, Y.; Iyanagi, T. Functional co-expression of xenobiotic metabolizing enzymes, rat cytochrome P450 1A1 and UDP-glucuronosyltransferase 1A6, in yeast microsomes. Biochim. Biophys. Acta, 2004, 1672, 86-92.
144. Dajani, R.; Sharp, S.; Graham, S.; Bethell, S. S.; Cooke, R. M.; Jamieson, D. J.; Coughtrie, M. W. Kinetic properties of human dopamine
145. Komori, R.; Amano, Y.; Ogawa-Ohnishi, M.; Matsubayashi, Y. Identification of tyrosylprotein sulfotransferase in Arabidopsis. Proc. Natl. Acad. Sci. USA, 2009, 106, 15067-15072.
146. Saribas, A. S.; Mobasseri, A.; Pristatsky, P.; Chen, X.; Barthelson, R.; Hakes, D.; Wang, J. Production of N-sulfated polysaccharides using yeast-expressed N-deacetylase/N-sulfotransferase-1 (NDST- 1). Glycobiology, 2004, 14, 1217-1228.
147. Zhou, X.; Chandarajoti, K.; Pham, T. Q.; Liu, R.; Liu, J. Expression of heparan sulfate sulfotransferases in Kluyveromyces lactis and preparation of 3′-phosphoadenosine-5′-phosphosulfate. Glycobiology, 2011, 21, 771-780.
148. Elsby, R.; Kitteringham, N. R.; Goldring, C. E.; Lovatt, C. A.; Chamberlain, M.; Henderson, C. J.; Wolf, C. R.; Park, B. K. Increased constitutive c-Jun N-terminal kinase signaling in mice lacking glutathione S-transferase Pi. J. Biol. Chem., 2003, 278, 22243-22249.
149. Sun, K. H.; Chang, K. H.; Clawson, S.; Ghosh, S.; Mirzaei, H.; Regnier, F.; Shah, K. Glutathione-S-transferase P1 is a critical regulator of Cdk5 kinase activity. J. Neurochem., 2011, 118, 902-914.
150. Black, S. M.; Beggs, J. D.; Hayes, J. D.; Bartoszek, A.; Muramatsu, M.; Sakai, M.; Wolf, C. R. Expression of human glutathione Stransferases in Saccharomyces cerevisiae confers resistance to the anticancer drugs adriamycin and chlorambucil. Biochem. J., 1990, 268, 309-315.
151. Paladino, G.; Weibel, B.; Sengstag, C. Heterocyclic aromatic amines efficiently induce mitotic recombination in metabolically competent Saccharomyces cerevisiae strains. Carcinogenesis, 1999, 20, 2143-2152.